u 93631 has been researched along with tert-butylbicyclophosphorothionate in 1 studies
| Studies (u 93631) | Trials (u 93631) | Recent Studies (post-2010) (u 93631) | Studies (tert-butylbicyclophosphorothionate) | Trials (tert-butylbicyclophosphorothionate) | Recent Studies (post-2010) (tert-butylbicyclophosphorothionate) |
|---|---|---|---|---|---|
| 7 | 0 | 3 | 465 | 0 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, DB; Dillon, GH; Hamilton, BJ; Im, WB; Pregenzer, JF | 1 |
1 other study(ies) available for u 93631 and tert-butylbicyclophosphorothionate
| Article | Year |
|---|---|
[4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability.
Topics: Animals; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Ion Channels; Ligands; Picrotoxin; Quinoxalines; Rats; Receptors, GABA-A; Zinc | 1995 |